Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 63 P374 | DOI: 10.1530/endoabs.63.P374

1CHU Nantes, Nantes, France; 2Hôpital Pitié-Salpêtrière (AP-HP), Paris, France; 3CHU Angers, Angers, France; 4CHU Limoges, Nantes, France; 5Centre Hospitalier Lyon-Sud, Lyon, France; 6CHU Nancy, Nancy, France; 7CHD Vendée, La Roche-sur-Yon, France; 8UMR INSERM 1246-SPHERE, Nantes, France.


Introduction: Health-related Quality of Life (HR-QoL) is usually impaired in patients with thyroid diseases compared to the general population. Thyroidectomy is largely performed in case of benign thyroid disease, and can be associated with severe long-term complications: vocal cord palsy (VCP), hypoparathyroidism. Our goal was to report the long-term HR-QoL outcomes after thyroidectomy using the MOS 36-item short form health survey (SF-36) self-questionnaire.

Methods: The prospective ThyrQoL multicenter trial (NCT02167529) included 800 patients who underwent total thyroidectomy in seven French referral hospitals between 2014 and 2017. Exclusion criteria were extensive malignant disease, age <18 years, preoperative voice disorders with confirmed VCP. HR-QoL was assessed using the SF-36 self-questionnaire with a 6 months follow-up.

Results: We observed a significant improvement of HR-QoL 6 months after surgery (P<0.0001). Postoperative complications were associated with a non-significant impairment of HR-QoL. In multivariate analysis, Graves’ disease was associated with a significant improvement of HR-QoL (OR =2.39 [1.49; 3.84]) and thyroid malignant disease with an impairment of HR-QoL (OR =1.44 [0.99; 2.08]) after total thyroidectomy. Compared to general population, HR-QoL was significantly impaired in patient with thyroid disease (P<0.0001); despite significant postoperative improvement, HR-QoL remained significantly impaired (P<0.0001) after thyroid surgery compared to general population.

Conclusions: We observed a significant improvement of HR-QoL 6 months after total thyroid surgery for benign and non-extensive malignant thyroid disease. Our results may help provide better information to both patients and physicians/surgeons, in order to choose the most appropriate treatment.

Volume 63

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.